Literature DB >> 16697521

Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision.

Vincenzo Ficarra1, Guido Martignoni, Antonio Galfano, Giacomo Novara, Stefano Gobbo, Matteo Brunelli, Maurizio Pea, Filiberto Zattoni, Walter Artibani.   

Abstract

OBJECTIVES: To evaluate concordance, using the kappa statistic, between tumour histotypes assigned at initial diagnosis and those after slide revision, and to assess the independent predictive value of reviewed tumour histotype.
MATERIALS AND METHODS: We analysed records of 491 patients who had undergone partial or radical nephrectomy for renal cell carcinoma (RCC) in our department from 1986 to 2000. Pathologic slides were reviewed by one uropathologist blinded to original diagnoses and follow-up data, who reassigned histologic subtype and nuclear grades.
RESULTS: Concordance between original and reviewed histotypes was substantial (kappa = 0.52). Data were affected by the year of initial diagnosis: Concordance was moderate (kappa = 0.43) in patients treated from 1986 to 1997 and substantial (kappa = 0.73) in those observed thereafter. The original histotype did not stratify the cancer-related outcome. According to the reviewed histotypes, the 5-year cancer-specific survival probabilities of conventional, papillary and chromophobe RCC patients were 81.3%, 90.1% and 100%, respectively (p = 0.009). Patients with conventional RCC showed significantly lower cancer-specific survival than those with papillary or chromophobe RCC, even in the cases with locally advanced (p = 0.04) or high-grade (p = 0.02) neoplasms. The reviewed histologic subtype was not an independent prediction of cancer-specific survival on multivariate analysis.
CONCLUSION: Concordance between histologic subtype assigned before 1997 and after slide revision was only moderate. In univariate analysis, reviewed tumour histotype stratified cancer-related outcome, but the data of multivariate analysis were strongly influenced by the prevalent number of conventional RCC.

Entities:  

Mesh:

Year:  2006        PMID: 16697521     DOI: 10.1016/j.eururo.2006.04.009

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  26 in total

Review 1.  [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].

Authors:  M Staehler; N Haseke; G Schöppler; T Stadler; G Heinemann; C G Stief
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

2.  Accurate molecular classification of renal tumors using microRNA expression.

Authors:  Eddie Fridman; Zohar Dotan; Iris Barshack; Miriam Ben David; Avital Dov; Sarit Tabak; Orit Zion; Sima Benjamin; Hila Benjamin; Hagit Kuker; Camila Avivi; Kinneret Rosenblatt; Sylvie Polak-Charcon; Jacob Ramon; Nitzan Rosenfeld; Yael Spector
Journal:  J Mol Diagn       Date:  2010-07-01       Impact factor: 5.568

Review 3.  Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines.

Authors:  Giovanni M Frascà; Fabiana Brigante; Alessandro Volpe; Laura Cosmai; Maurizio Gallieni; Camillo Porta
Journal:  J Nephrol       Date:  2018-10-16       Impact factor: 3.902

4.  Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas.

Authors:  Yael Spector; Eddie Fridman; Shai Rosenwald; Sofia Zilber; Yajue Huang; Iris Barshack; Orit Zion; Heather Mitchell; Mats Sanden; Eti Meiri
Journal:  Mol Oncol       Date:  2013-03-26       Impact factor: 6.603

5.  Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.

Authors:  Sandra Steffens; Frederik C Roos; Martin Janssen; Frank Becker; Julie Steinestel; Mahmoud Abbas; Konrad Steinestel; Gerd Wegener; Stefan Siemer; Joachim W Thüroff; Rainer Hofmann; Michael Stöckle; Mark Schrader; Arndt Hartmann; Kerstin Junker; Markus A Kuczyk; Andres J Schrader
Journal:  Virchows Arch       Date:  2014-09-02       Impact factor: 4.064

6.  Relating prognosis in chromophobe renal cell carcinoma to the chromophobe tumor grading system.

Authors:  Elizabeth P Weinzierl; Alan E Thong; Jesse K McKenney; Seung Hyun Jeon; Benjamin I Chung
Journal:  Korean J Urol       Date:  2014-04-10

7.  Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.

Authors:  Kunpeng Liu; Yuan Ren; Lijuan Pang; Yan Qi; Wei Jia; Lin Tao; Zhengyan Hu; Jin Zhao; Haijun Zhang; Li Li; Haifeng Yue; Juan Han; Weihua Liang; Jianming Hu; Hong Zou; Xianglin Yuan; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

8.  Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma.

Authors:  Patrick E Teloken; R Houston Thompson; Satish K Tickoo; Angel Cronin; Caroline Savage; Victor E Reuter; Paul Russo
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

9.  [Value of the postoperative Störkel score. Predict disease-free survival of patients with surgically resected renal cell carcinoma].

Authors:  M May; S Brookman-Amissah; S Pflanz; N Knoll; J Roigas; S Gunia; B Hoschke; F Kendel
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

Review 10.  Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.

Authors:  Theodore F Logan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.